Specify a stock or a cryptocurrency in the search bar to get a summary
Carmat
CXTCarmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France. Address: 36, avenue de l'Europe, Vélizy-Villacoublay, France, 78140
Analytics
WallStreet Target Price
11.27 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CXT
Dividend Analytics CXT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CXT
Stock Valuation CXT
Financials CXT
Results | 2019 | Dynamics |